San Diego Clinic
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Arthritis Treatment
- Chelation Therapy
La Jolla, CA
Stem Cell Therapy clinics in La Jolla
La Jolla supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Scripps Memorial La Jolla, UC San Diego Jacobs Medical Center, Sanford Burnham Prebys, and Salk Institute, and stem cell practice in the area spans Torrey Pines Mesa, the Village of La Jolla, and UTC. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. SB 1004 (2017) requires written disclosure when stem cell therapy is not FDA-approved. The Medical Board of California regulates physician practice under Business and Professions Code 651. Proposition 71 (2004) established the California Institute for Regenerative Medicine (CIRM). The FDA secured a 2022 permanent injunction against the California Stem Cell Treatment Center over non-compliant adipose SVF products. The 4 La Jolla clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and California Medical Board licensure checks.
Sanford Stem Cell Clinical Center at UC San Diego Health
- Multiple Sclerosis (MS) Treatment
- Arthritis Treatment
- Stem Cell Therapy
Essential Medicine
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- PRP Therapy
- Ozone Therapy
ZignaGenix
- Multiple Sclerosis (MS) Treatment
- Arthritis Treatment
- Lyme Disease Treatment
- Erectile Dysfunction (ED) Treatment
- Stem Cell Therapy
MD on staff
San Diego Center for Restorative Medicine
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- PRP Therapy
- Shockwave Therapy
Integrative Health Solutions
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- PRP Therapy
- IV Hydration
MD on staff
Kadima Neuropsychiatry Institute
- Ozone Therapy
- IV Therapy
- Transcranial Magnetic Stimulation (TMS)
- Hyperbaric Oxygen Therapy (HBOT)
- Ketamine Therapy
MD on staff
Essential Medicine
- Ozone Therapy
- IV Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Ketamine Therapy
- Arthritis Treatment
Regulatory context
A note on California's stem cell therapy rules.
California cellular therapy providers are subject to 21 CFR Part 1271. Minimally manipulated human cells, tissues, and cellular and tissue-based products used for homologous use are regulated under Section 361 without premarket approval. Products that are more than minimally manipulated, used non-homologously, or combined with a drug or device are regulated as biologics under Section 351 and require an IND for clinical use or a BLA for marketing. Adipose-derived stromal vascular fraction, culture-expanded mesenchymal stem cells, and exosomes used for orthopedic, cosmetic, neurologic, and longevity indications are generally Section 351 products.
-
California Senate Bill 1004 (2017, Health and Safety Code Section 1644.5)
Requires providers of non-FDA-approved stem cell therapies to post a notice to patients disclosing that the treatment has not been approved by the FDA. -
California Proposition 71 (2004) and Proposition 14 (2020), California Institute for Regenerative Medicine
Established and refunded CIRM to fund regenerative medicine research under strict scientific and ethical oversight. -
California Business and Professions Code Section 651
Prohibits false, misleading, or deceptive medical advertising, regularly cited in disciplinary actions against stem cell marketing. -
California Business and Professions Code Section 2052 (Medical Practice Act)
Governs physician licensure and prohibits unlicensed practice of medicine, including unauthorized administration of biologic injections.
California has been a focal point of federal enforcement. In United States v California Stem Cell Treatment Center (2022), the Ninth Circuit upheld FDA authority to regulate stromal vascular fraction as a Section 351 drug, resulting in a permanent injunction against the clinic. The FDA has issued multiple warning letters to California providers marketing stem cell and exosome therapies. The Medical Board of California has disciplined physicians for false advertising under BPC 651 and for administering unapproved biologics. The California Department of Public Health enforces tissue bank licensing. Class-action consumer suits against regenerative clinics have produced settlements.